NCT02849691

Brief Summary

Dipeptidyl-peptidase-4 (DPP4) is an important regulator of incretins and inflammation, and participates in the pathophysiological process of acute myocardial infarction (AMI). However clinical data of DPP4a in AMI patients is sparse. This study was to investigate the role of plasma DPP4 activity (DPP4a) in patients with ST-segment elevation myocardial infarction (STEMI) treated with percutaneous coronary intervention (PCI). This was a analysis of consecutive patients conducted at a tertiary referral center from January 2014 to October 2015. The investigators included 747 STEMI-patients, treated with PCI from January 2013 to October 2015. Blood samples were collected immediately at admission. The patients were divided into four groups according to DPP4a quartile.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
747

participants targeted

Target at P75+ for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2014

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2015

Completed
10 months until next milestone

First Submitted

Initial submission to the registry

July 24, 2016

Completed
5 days until next milestone

First Posted

Study publicly available on registry

July 29, 2016

Completed
Last Updated

July 29, 2016

Status Verified

July 1, 2016

Enrollment Period

1.7 years

First QC Date

July 24, 2016

Last Update Submit

July 26, 2016

Conditions

Dipeptidyl-peptidase-4STEMIPCINo-reflowBleeding

Outcome Measures

Primary Outcomes (1)

  • a change in the prevalence of no-reflow

    TIMI flow grade of \<3 with a myocardial blush grade of 0-1 was defined as angiographic no-reflow

    immediately after PCI

Secondary Outcomes (3)

  • in-hospital major adverse cardiac or cerebrovascular events

    up to 2 week after PCI (until discharge)

  • in-hospital complications

    up to 2 week after PCI (until discharge)

  • in-hospital major bleeding

    up to 2 week after PCI (until discharge)

Study Arms (4)

Quartile 1

Quartile 1 of plasma DPP4 activity

Quartile 2

Quartile 2 of plasma DPP4 activity

Quartile 3

Quartile 3 of plasma DPP4 activity

Quartile 4

Quartile 4 of plasma DPP4 activity

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

PLA general hospital (PLAGH) is a large national tertiary-care center in the Beijing, China. The investigators enrolled all patients consecutively hospitalized in PLAGH, with a diagnosis of STEMI and needed PCI.

You may qualify if:

  • a diagnosis of STEMI and needed PCI

You may not qualify if:

  • patients with cancer
  • patients who used DPP4 inhibitor
  • patients who used GLP1 analogue

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (5)

  • Windecker S, Bax JJ, Myat A, Stone GW, Marber MS. Future treatment strategies in ST-segment elevation myocardial infarction. Lancet. 2013 Aug 17;382(9892):644-57. doi: 10.1016/S0140-6736(13)61452-X.

    PMID: 23953388BACKGROUND

  • Zhong J, Rajagopalan S. Dipeptidyl Peptidase-4 Regulation of SDF-1/CXCR4 Axis: Implications for Cardiovascular Disease. Front Immunol. 2015 Sep 25;6:477. doi: 10.3389/fimmu.2015.00477. eCollection 2015.

    PMID: 26441982BACKGROUND

  • Zhong J, Maiseyeu A, Davis SN, Rajagopalan S. DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition. Circ Res. 2015 Apr 10;116(8):1491-504. doi: 10.1161/CIRCRESAHA.116.305665.

    PMID: 25858071BACKGROUND

  • Connelly KA, Zhang Y, Advani A, Advani SL, Thai K, Yuen DA, Gilbert RE. DPP-4 inhibition attenuates cardiac dysfunction and adverse remodeling following myocardial infarction in rats with experimental diabetes. Cardiovasc Ther. 2013 Oct;31(5):259-67. doi: 10.1111/1755-5922.12005.

    PMID: 22963483BACKGROUND

  • Shigeta T, Aoyama M, Bando YK, Monji A, Mitsui T, Takatsu M, Cheng XW, Okumura T, Hirashiki A, Nagata K, Murohara T. Dipeptidyl peptidase-4 modulates left ventricular dysfunction in chronic heart failure via angiogenesis-dependent and -independent actions. Circulation. 2012 Oct 9;126(15):1838-51. doi: 10.1161/CIRCULATIONAHA.112.096479. Epub 2012 Oct 3.

    PMID: 23035207BACKGROUND

MeSH Terms

Conditions

ST Elevation Myocardial InfarctionHemorrhage

Condition Hierarchy (Ancestors)

Myocardial InfarctionMyocardial IschemiaHeart DiseasesCardiovascular DiseasesVascular DiseasesInfarctionIschemiaPathologic ProcessesPathological Conditions, Signs and SymptomsNecrosis

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr.

Study Record Dates

First Submitted

July 24, 2016

First Posted

July 29, 2016

Study Start

January 1, 2014

Primary Completion

October 1, 2015

Last Updated

July 29, 2016

Record last verified: 2016-07